Abstract: The present invention relates to the use of pyridine N-oxide based azo dyes and their metal complexes in optical layers for optical data recording, preferably for optical data recording using a blue laser with a wavelength up to 450 nm or a red laser with a wavelength up to 650 nm. The invention further relates to a write only read many (WORM) type optical recording medium capable of recording and reproducing information with radiation of a blue or red laser, which employs a pyridine N-oxide based azo dye or a respective metal complex in the optical layer.

Abstract: Emissive phosphorescent organometallic compounds are described that produce improved electroluminescence, particularly in the blue region of the visible spectrum. Organic light emitting devices employing such emissive phosphorescent organometallic compounds are also described. Also described is an organic light emitting layer including a host material having a lowest triplet excited state having a decay rate of less than about 1 per second; a guest material dispersed in the host material, the guest material having a lowest triplet excited state having a radiative decay rate of greater than about 1×105 or about 1×106 per second and wherein the energy level of the lowest triplet excited state of the host material is lower than the energy level of the lowest triplet excited state of the guest material.

Abstract: The present invention provides an adenine modified solid, ordered, mesoporous, bifunctional, organo-inorganic silica-based catalyst, its method of preparation and also a process for the production of cyclic carbonates of the formula hereinbelow wherein R?H, CH2Cl, CH3, C4H9, C6H11, C6H5.

Abstract: It is an object of the present invention to provide a substance capable of emitting phosphorescence. In addition, it is an object of the present invention to provide a light-emitting element that is excellent in chromaticity. One aspect of the present invention is an organometallic complex having a structure represented by a general formula (1). In the general formula (1), R1 to R4 are each any one of hydrogen, a halogen element, an acyl group, an alkyl group, an alkoxyl group, an aryl group, a cyano group, and a heterocyclic group. In addition, R5 to R13 are each any one of hydrogen, an acyl group, an alkyl group, an alkoxyl group, an aryl group, a heterocyclic group, and an electron-withdrawing group. An organometallic complex having such a structure can emit phosphorescence with higher emission intensity.

Abstract: Supramolecular complexes that target and cleave DNA are provided. The supramolecular complexes include at least one metal-to-ligand charge transfer (MLCT) light absorbing unit, at least one Pt based DNA binding unit, and at least one bridging unit that serves to connect the components. The Pt-based DNA binding unit binds the complex to DNA, and the MLCT unit absorbs light, thereby sensitizing molecular oxygen to produce reactive oxygen species in close proximity to the complex and the bound DNA. The reactive oxygen species cleave the bound DNA.

Abstract: Organometallic complexes suitable as olefin metathesis catalysts are provided. The complexes are Group 8 transition metal carbenes bearing a cationic substituent and having the general structure (I) wherein M is a Group 8 transition metal, L1 and L2 are neutral electron donor ligands, X1 and X2 are anionic ligands, m is zero or 1, n is zero or 1, and R1, W, Y, and Z are as defined herein. Methods for synthesizing the complexes are also provided, as are methods for using the complexes as olefin metathesis catalysts.

Abstract: An electroluminescence device having a layer containing a specific metal coordination compound is provided. The metal coordination compound is represented by formula (1) below: MLmL?n,??(1) wherein M is a metal atom of Ir, Pt, Rh or Pd; L and L? are mutually different bidentate ligands; m is 1, 2 or 3 and n is 0, 1 or 2 with the proviso that m+n is 2 or 3; a partial structure MLm is represented by formula (2) shown below and a partial structure ML?n is represented by formula (3) or (4) shown below: The metal coordination compound of the formula (1) is characterized by having at least one aromatic substituent for at least one of CyN1, CyN2, CyC1 and CyC2. The metal coordination compound having the aromatic substituent is effective in providing high-efficiency luminescence, long-term high luminance, and less deterioration by current passing.

Abstract: There are provided compounds of Ir(III) having ?-diketimine ligands. The complexes having Formulae I: where: L is the same or different at each occurrence and is a cyclometalating bidentate monoanionic ligand coordinated through a nitrogen atom and a carbon atom; R1 and R3 can be the same or different and are independently selected from the group consisting of hydrogen, halogen, alkyl, aryl, alkylaryl and heterocyclic groups; and R10 and R11 can be the same or different and are independently selected from the group consisting of hydrogen, halogen, alkyl, aryl, alkylaryl, trialkylsilyl, triarylsilyl, and heterocyclic groups; and R2 is selected from the group consisting of hydrogen, alkyl, aryl, alkylaryl, heterocyclic groups, and fluorine wherein adjacent R groups can join together to form 5- or 6-membered rings. R8 is H, F, or alkyl There are also provided electronic devices containing such compounds.

Abstract: A photosensitizer dye is provided. The photosensitizer dye contains a Ru complex represented by the following formula (1): wherein Y1 and Y2 independently represent hydrogen atom (H), lithium (Li), sodium (Na) or tetra-alkyl ammonium groups (as represented by the following general formula (2)). wherein A, B, C and D independently represents CmH2m+1 (m=1˜6).

Abstract: Provided are a high-efficiency, photoluminescent heteronuclear copper (I)-iridium (III) complex and an organic electroluminescent device using the complex. The photoluminescent heteronuclear copper (I)-iridium (III) complex can be used to form an organic layer of an organic electroluminescent device, can emit light of 590-630 nm as a high-efficiency, photoluminescent material, and provides a high brightness and a low turn-on voltage.

Abstract: The present invention provides an improved process for the preparation of carbamates with high selectivity of pharmaceutical interest by an eco-friendly, non-toxic, phosgene-/isocyanate-/CO-free clean route through a reaction of amine, organic halide compound and carbon dioxide in the presence of a solid, reusable catalyst at moderate conditions and does not require additional cocatalyst/promoter as well as solvent

Abstract: A photosensitizer dye is provided. The photosensitizer dye contains a Ru complex represented by the following formula (1): wherein Y1 and Y2 independently represents hydrogen atom (H), lithium (Li), sodium (Na) or tetra-alkyl ammonium groups (as represented by the following general formula (2)). Formula (2): wherein A, B, C and D independently represents CmH2m+1 (m=1˜6).

Abstract: Provided are an organometallic complex providing highly efficient phosphorescence and an organic electroluminescence device using the organometallic complex represented by Formula 1: MLmL?n where M is Ir, Os, Pt, Pb, Re, Ru or Pd, L and L? are different bidentate ligands, m is 1, 2 or 3, and n is 3?m. The organometallic complex can be used to form an organic layer of the organic electroluminescence device, efficiently emits light of a wavelength corresponding to red light, and has high brightness and low operating voltage.

Abstract: Provided is a cyclometalated transition metal complex represented by Formula 1: The cyclometalated transition metal complex contains a new ancillary ligand having a carboxylate acid or the like connected to a hetero ring, so that it can efficiently emit red light from a phosphorous material through intersystem crossing (ISC) to form triplet excitons and then metal to ligand charge transfer (MLCT). An organic light emitting device manufactured using the transition metal complex shows excellent luminous efficiency and external quantum efficiency.

Abstract: Provided are an organometallic complex providing highly efficient phosphorescence and an organic electroluminescence device using the same. The organometallic complex can be used to form an organic layer of the organic electroluminescence device, efficiently emits light of a wavelength corresponding to red light, and has high brightness and low operating voltage.

Abstract: The present invention relates to catalysts of transition metal complexes of N-heterocyclic carbenes, their methods of preparation and their use in chemical synthesis. The synthesis, ease-of-use, and activity of the compounds of the present invention are substantial improvements over in situ catalyst generation. Further, the transition metal complexes of N-heterocyclic carbenes of the present invention may be used as precatalysts in metal-catalyzed cross-coupling reactions.

Abstract: The present invention is generally directed to electroluminescent Ir(III) complexes which have emission maxima in the red-orange to red region of the visible spectrum and devices that are made with the Ir(III) complexes.

Abstract: A light-emitting material comprises a compound having a partial structure represented by the following formulas (8), (20) and tautomers thereof: wherein the variables are as defined in the specification.

Abstract: An organometallic complex according to the present invention comprises a structure represented by the following general formula (1). In the formula, R1 to R5 are any one selected from the group consisting of hydrogen, a halogen element, an acyl group, an alkyl group, an alkoxyl group, an aryl group, a cyano group, and a heterocyclic group, Ar is an aryl group having an electron-withdrawing group or a heterocyclic group having electron-drawing group, and M is an element of Group 9 or an element of Group 10.

Abstract: A class of organic metal complexes with mixed ligands for organic light emitting diodes are designed and characterized as the formula:(L2L3M)n. In this formula: L2 is a bidentate ligand which has at least one coordinate atom of oxygen; L3 is a tridentate ligand with three chelate points; M is trivalent metal selected from the group consisting of Al, Ga, In, Tl, and Ir; and n is an integer of from 1 to 2. In Formula (3), X, Y independently represent CH or N and II, III are unsubstituted or substituted aryl or heteroalkyl groups. The substituent groups can be alkyl having 1–8 carbon atoms, halogen, cyano, amino, amido, sulfonyl, carbonyl, aryl, or heteroalkyl groups such as furan, thiophene, pyrrole, pyridine, etc.

Abstract: The present invention is directed to ceramide analog compounds of general formula (I) the process for their preparation and use for the preparation of pharmaceutical formulations for the treatment of tumors

Abstract: The present invention is generally directed to electroluminescent Pt(II) complexes which have emission maxima across the visible spectrum, and devices that are made with the Pt(II) complexes.

Abstract: The present invention concerns novel platinum complexes in which at least one of the amine ligand is a non-planar heterocyclic aliphatic amine. The platinum complexes may be in a trans or cis configuration and were found to posses therapeutic activites. Thus, the present concerns novel platinum complexes, pharmaceutical compositions comprising them and other uses thereof.

Abstract: The present invention describes novel organometallic compounds which are phosphorescence emitters. Such compounds can be used as active components (=functional materials) in a series of different types of application which can be classed within the electronics industry in the broadest sense. The compounds according to the invention are described by the formulae (I), (Ia), (II) and (IIa).

Abstract: Complexes of organic ligands with a metal ion exhibit unique conformation and spectroscopic properties upon changes in oxidation state of the metal ion. The metal is a redox-active metal ion and may possess additional ligands bonded to it. The organic ligand has three “arms” that are linked together at a central atom; each arm contains atoms that may also coordinate to the metal ion. At least two of the arms possess chromophoric properties. At least one arm contains two different groups that may coordinate to the metal ion. In one oxidation state, a first atom binds to the metal. In a second oxidation state, a second atom binds to the metal. This change in coordination of the metal ion results in a rotation of one of the arms, which changes the orientation of another group, which inverses the orientation of the two chromophoric species with respect to one another.

Abstract: A series of Pt(II) complexes having the following formula are disclosed: X1 and X2 independently are C or N, X1 can also locate at another position of the hexagonal ring, when X1 is N; R1 is H, C1–C8 alkyl, or C1–C4 perfluoroalkyl, R2 is H, R1 and R2 together are C4–C8 alkylene, or R1 and R2 together are bridged carbocyclic C4–C12 alkylene, when X2 is C; R1 is H, C1–C8 alkyl, or C1–C4 perfluoroalkyl, and R2 is omitted, when X2 is N; R7 is H or methyl, and R8 is omitted, when X1 is N; R7 is H or methyl, R8 is H or methyl, or R7 and R8 together are when X1 is C.

Abstract: An electroluminescence device having a layer containing a specific metal coordination compound is provided. The metal coordination compound is represented by formula (1) below: MLmL?n??(1), wherein M is a metal atom of Ir, Pt, Rh or Pd; L and L? are mutually different bidentate ligands; m is 1, 2 or 3 and n is 0, 1 or 2 with the proviso that m+n is 2 or 3; a partial structure MLm is represented by formula (2) shown below and a partial structure ML?n is represented by formula (3) or (4) shown below: The metal coordination compound of the formula (1) is characterized by having at least one aromatic substituent for at least one of CyN1, CyN2, CyC1 and CyC2. The metal coordination compound having the aromatic substituent is effective in providing high-efficiency luminescence, long-term high luminance, and less deterioration by current passing.

Abstract: This invention features a supramolecule having the following structure: M is a transition metal atom that is rhenium (Re), manganese (Mn), chromium (Cr), molybdenum (Mo), tungsten (W), iron (Fe), ruthenium (Ru), or osmium (Os); Y is a nitrogen-based didentate ligand; A is O, S, Se, or Te; R is C3˜C16 alkyl, (CH2)n-aryl, or (CH2)n-aryl-(O—C1˜C16 alkyl)p, in which n is 0-15, p is 1-3; and m is 1, 2, 3, 4, or 5.

Abstract: The invention provides a probe for detecting a highly ordered structural site of a nucleic acid of a gene by specifically binding with the structural site to generate an electrochemical response. The inventive probe comprises a cyclic ligand containing ferrocenyl group and a DNA threading intercalating moiety, such as 1,4,5,8-tetrasubstituted naphthalene, 9,10-disubstituted anthracene, and 1,5-disubstituted anthraquinone. Current of the cyclic ligand is not observed due to interaction such as stacking or so called charge transfer between ferrocenyl group and the DNA threading intercalating moiety in conventional electrolyte. The binding of the ligand with a highly ordered structural site of a single stranded nucleic acid, where nucleic base inserts between the cavity of cyclic ligand, inhibits the intramolecular interaction of the ligand to convert the ligand into its electrically active form, and as a result, current is observed.

Abstract: The present invention is generally directed to electroluminescent Ir(III) compounds with phosphinoalkoxides and phenylpyridines or phenylpyrimidines, and devices that are made with the Ir(III) compounds.

Abstract: The present invention relates to a method for the preparation of cephalosporin antibiotic of the formula (II), which comprises hydrolyzing and halogenating the ester of formula (III) by photochemical irradiation in one pot using a halogenating agent in the absence or presence of a solvent, to produce compound of formula (I), activating the 4-halogeno-2-substitutedimino-3-oxo-butyric acid of formula (I) using conventional activation agents gives compound of formula (IV), condensing the activated compound of the formula (IV) with 7-amino cephem derivative of the formula (V) to produce a compound of formula (VI), and cyclizing the compound of formula (VI) with thiourea to give cephalosporin compounds of the formula (II).

Abstract: A method for producing biphenyl and its derivative comprising oxidatively coupling a benzene aromatic compound in the presence of a catalyst comprising a palladium salt, a copper salt, and a bidentate ligand compound capable of forming a complex with the palladium salt via the nitrogen atom and the oxygen atom in the molecule thereof in an atmosphere containing molecular oxygen. In particular, an improved method for selectively producing an asymmetrically substituted biphenyl derivative, such as a 2,3,3?,4?-biphenyltetracarboxylic acid tetraester, which comprises oxidatively coupling a substituted aromatic compound, such as a phthalic diester, in the presence of the catalyst in an atmosphere containing molecular oxygen without replenishing with a ligand.

Abstract: A production process, especially a continuous production process, for a biphenyltetracarboxylic acid tetraester characterized by carrying out, in parallel, a step of preliminarily mixing a phthalic acid diester and a palladium compound-containing catalyst to prepare a starting mixture, a step of continuously or intermittently supplying the starting mixture to a reactor, a step of conducting oxidative dimerization reaction of the phthalic acid diester in a temperature range of from 140° C. and lower than 250° C. while supplying molecular oxygen to the reactor to form a reaction mixture in the reactor, and a step of continuously or intermittently removing a portion of the reaction mixture from the reactor.

Abstract: The present invention relates to substituted boron or aluminum spiro compounds and their use in the electronic industry. The compounds of the invention are used as electron transport material, hole blocking material and/or as host material in organic electroluminescence and/or phosphorescence devices, as electron transport material in photocopiers, as electron acceptor or electron transport material in solar cells, as charge transport material in organic ICs (circuits) and in organic solid-state lasers or organic photodetectors.

Abstract: A cephem compound (particularly its crystal) represented by the formula [I], wherein X is CH3COOH, CH3CH2COOH or CH3CN, and n is 0 to 5, is useful as an antibacterial agent (particularly anti-MRSA agent) and shows superior quality such as high solid stability, possible long-term stable preservation and the like.

Abstract: The present invention relates to platinum antitumor drugs. In particular, it relates to platinum complexes having formula Ia or Ib or a pharmaceutically acceptable salt thereof wherein: each A is independently an anion; each B is independently halo, hydroxy, carboxylate, carbamate or a carbonate ester, Z is a substituted 5- or 6-membered, heterocyclic moiety wherein at least one substituent sterically hinders access of the Pt atom to a DNA strand of a tumor cell, and wherein Z is other than pyridine; and X is NH3 or mono- or dialkyl substituted NH3. which are active against cancer cells and have improved aqueous solubility and activity.

Abstract: The invention relates to a novel class of ligands, complexes comprising such ligands and a metal ion, and adducts of these metal complexes and a macromolecule. Pharmaceutical compositions and methods of making and using the ligand-metal complexes are also described. The invention also relates to the use of macromolecular adducts for enhancement of diagnostic imaging. In particular, the invention relates to (ethylene)-(propylene)-triaminepentaacetic acid (EPTPA) derivatives, a process for their production, and their use for the production of pharmaceutical agents for NMR diagnosis or radiodiagnosis or radiotherapy.

Abstract: A metal coordination compound having a basic structure represented by formula: MLmL′n (1), wherein M is a metal atom of Ir, Pt, Rh or Pd; L and L′ are mutually different bidentate ligands; m is 1, 2 or 3; wherein at least one bidentate ligand has a partial structure formed by condensation via an alkylene group having 2-10 carbon atoms, is provided. In an electroluminescence device composed of one or a plurality of organic films disposed between a cathode and an anode, at least one layer is a luminescence layer which is formed by incorporating luminescence molecules constituting the metal coordination compound having a structure of the formula (1) described above as a guest material in a host material thereby to provide an electroluminescence device producing luminescence at high efficiency and stably keeping a high luminance for a long period.

Abstract: A luminescence device that has an organic compound layer disposed between a pair of electrodes. This organic compound layer contains a metal coordination compound represented by the following formula (1) wherein M is Ir, Rh or Pd; n is 2 or 3; CyN is a substituted or unsubstituted cyclic group containing a nitrogen atom connected to M and capable of containing another nitrogen atom and/or sulfur atom; and CyC is a substituted or unsubstituted cyclic group containing a carbon atom connected to M and capable of containing a nitrogen atom and/or a sulfur atom.

Abstract: The present invention relates to novel hexacoordinated metathesis catalysts and to methods for making and using the same. The inventive catalysts are of the formula wherein: M is ruthenium or osmium; X and X1 are the same or different and are each independently an anionic ligand; L, L1′ and L2 are the same or different and are each independently a neutral electron donor ligand; and, R and R1 are each independently hydrogen or a substituent selected from the group consisting of C1-C20 alkyl, C2-C20 alkenyl, C2-C20 alkynyl, aryl, C1-C20 carboxylate, C1-C20 alkoxy, C2-C20 alkenyloxy, C2-C20 alkynyloxy, aryloxy, C2-C20 alkoxycarbonyl, C1-C20 alkylthio, C1-C20 alkylsulfonyl and C1-C20 alkylsulfinyl and silyl.

Abstract: Complexes of organic ligands with a metal ion exhibit unique conformation and spectroscopic properties upon changes in oxidation state of the metal ion. The metal is a redox-active metal ion and may possess additional ligands bonded to it. The organic ligand has three “arms” that are linked together at a central atom; each arm contains atoms that may also coordinate to the metal ion. At least two of the arms possess chromophoric properties. At least one arm contains two different groups that may coordinate to the metal ion. In one oxidation state, a first atom binds to the metal. In a second oxidation state, a second atom binds to the metal. This change in coordination of the metal ion results in a rotation of one of the arms, which changes the orientation of another group, which inverses the orientation of the two chromophoric species with respect to one another.

Abstract: The invention relates to a catalyst component and a catalyst system for the preparation of high molecular weight ethylene or alpha-olefin homopolymers, ethylene-alpha-olefin copolymers, terpolymers or tetrapolymers, in a polymerization process, which is expediently effected in solution, at elevated temperature, preferably at least 80 DEG C. The catalyst system comprises a group 4-6 metal, preferably group 4 metal, a cyclic ligand (such as a cyclopentadienyl-type ligand), which forms a delocalized pi-bond with the metal M, a monohapto bonded 1,3-diaza-2-imino heterocyclic ligand (such as an iminoimidazolidine-type ligand) and anionic ligands and a catalyst activator coupound.

Abstract: A metal coordination compound having a binuclear molecular structure represented by the following formula (1): wherein M1 and M2 independently denotes a metal atom selected from the group consisting of Ir, Pt, Rh, Pd, Ru and Os; P is a quadridentate ligand connected to M1 and M1; Q1 is a bidentate ligand connected to M1; Q2 is a bidentate ligand connected to M2; and n is 1 or 2.

Abstract: The present invention is generally directed to electroluminescent Ir(III) compounds, the substituted 2-phenylpyridines, phenylpyrimidines, and phenylquinolines that are used to make the Ir(III) compounds, and devices that are made with the Ir(III) compounds.

Abstract: The invention provides methods for treating cancer and compounds that are useful for the treatment of tumors, as well as pharmaceutical compositions comprising the compounds, and synthetic methods and intermediates useful for preparing the compounds.

Abstract: Nucleic acid labeling compounds containing heterocyclic derivatives are disclosed. The heterocyclic derivative containing compounds are synthesized by condensing a heterocyclic derivative with a cyclic group (e.g. a ribofuranose derivative). The labeling compounds are suitable for enzymatic attachment to a nucleic acid, either terminally or internally, to provide a mechanism of nucleic acid detection.

Abstract: An organometallic framework material is prepared by a process which comprises reacting a fluid mixture comprising a metal salt with at least one one at least bidentate organic compound capable of coordination to metal ions in the presence of at least one base and a solvent, where the solvent comprises at least one cyclic amide (lactam) and/or at least one cyclic ester (lactone).

Abstract: The invention provides low molecular weight or polymeric organic materials in which at least one hydrogen atom is replaced by a group of the formula (A) 1

Abstract: This invention relates to high purity hydrogen ion buffers and in particular amino-organosulfonic acid zwitterionic compositions having low metal content. The concentration of any single metal in the composition is no greater than about 500 ppb, and ideally is less than about 20 ppb.

Abstract: The invention relates to ligand complexes characterised by the presence of a piperazineNONOate residue with metal cations where the cations derive from a transition metal or zinc in a stable oxidation state. These complexes are nitric oxide donors and exert an endothelio-protective effect on the coronary district and stimulate re-endothelialization and angiogenesis processes. The invention comprises a preparation process and the therapeutic use of said compounds.